FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

BACKGROUND: Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis aimed to determine whether cetuximab improves respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinemann, Volker, von Weikersthal, Ludwig Fischer, Decker, Thomas, Kiani, Alexander, Kaiser, Florian, Al-Batran, Salah-Edin, Heintges, Tobias, Lerchenmüller, Christoph, Kahl, Christoph, Seipelt, Gernot, Kullmann, Frank, Moehler, Markus, Scheithauer, Werner, Held, Swantje, Miller-Phillips, Lisa, Modest, Dominik Paul, Jung, Andreas, Kirchner, Thomas, Stintzing, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851157/
https://www.ncbi.nlm.nih.gov/pubmed/33154570
http://dx.doi.org/10.1038/s41416-020-01140-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851157/
https://www.ncbi.nlm.nih.gov/pubmed/33154570
http://dx.doi.org/10.1038/s41416-020-01140-9

Ejemplares similares